We bring together industry experts from the business and science community working together to bring revolutionary treatment to the mental healthcare landscape.
Chief Executive Officer
- An experienced Corporate Director and CEO: Doug has chaired the board of directors of a NASDAQ-listed company and as a CEO for the past 12 years has built and turned-around three pharmaceutical companies.
- During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents and has raised $4 billion of both public and private capital.
- Led the turnaround of Norwich Pharmaceuticals alongside investors and became the Founding CEO of parent company, Alvogen Group. During his 5.5 year tenure as CEO, Alvogen grew from inception to $450 million in revenues across 35 countries.
- In early 2014, Doug led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising $65 million. Within the first year of taking the helm as Chairman and CEO, Doug rebuilt the management team and board of directors, combined several operating locations, and grew the company’s enterprise value from $80 million to around $800 million. Under Doug’s leadership, Pernix raised $465 million of capital.
- From November 2017 to July 2020, Doug was a Director and CEO of Tedor Pharma, a family-owned contract manufacturing business. Doug’s efforts to turnaround the business resulted in 60% revenue growth in 2019, leading to Tedor being recognized as one of America’s fastest-growing companies, making it to the 2020 Inc 5000 list.
- Former Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including 25+ banks, to fund the company’s growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.
- Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012. Doug is an enthusiastic traveler, having traveled to over 45 countries, is an avid reader and enjoys cooking and boating.
Co-Founder, Executive Chairman and President
- Co-founder and Managing Director of Trinity Venture Partners Inc., a boutique merchant bank.
- Veteran founder, investor, operator and advisor to disruptive companies, he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm.
- Successfully raised hundreds of millions for various companies and navigated value creation, various exits and liquidity events for investors and shareholders.
- Bachelor of Science Major in Anatomy and Cell Biology and Minor in Psychology from McGill University.
- Bachelor of Laws from the University of Windsor.
Chief Operating Officer
- Former Chief Quality, Patient Safety, HSE & Risk Officer at UCB, Inc leading a team of 1500+ colleagues in 54 countries.
- Former President at UCB, Inc. leading US commercial operations through the restructuring into CNS and Immunology Business Units with annualized 27% P&L growth ($2.2B in revenue).
- Various Director level research, regulatory and managerial roles at Eli Lilly from 1997 to 2006.
Chief Compliance, Ethics & Administrative Officer
- Former Lead Compliance Program Designer of the non-medical cannabis compliance program at a major Canadian retailer.
- ISO 19600 Certified Senior Lead Compliance Manager.
- PROSCI Certified Change Management Practitioner.
- Vast experience and knowledge in the design and operation of foundational programs (regulatory compliance, operational) and organizational design & strategy implementation and execution.
Chief Medical Officer
- Qualified psychiatrist and pharmaceutical physician with over 20 years of clinical and drug development experience.
- Successfully progressed numerous candidate drugs through preclinical development and early phase clinical trials to proof-of-concept studies
- Experienced in leading global teams overseeing development of novel medications across a range of psychiatric indications including treatment resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance use disorders.
Alex Nivorozhkin Ph.D
Chief Scientific Officer
- Lead NCE inventor of multiple successfully partnered drug discovery and development programs.
- Technology developer of the proprietary formulations for CNS drugs.
- Seasoned medicinal chemist, drug delivery expert and founder of multiple biotech companies.
Michael Palfreyman Ph.D.
Chief R&D Officer
- 30 years of preclinical/clinical development experience: Scriptgen, EnVivo Pharma, Sanofi, GSK, Amorsa Therapeutics, and others.
- Successfully led multiple IND filings and clinical programs.
- Significant portfolio of CNS therapeutics patents and commercial products.
Chief Innovations Officer
- Research Administrator for the Center for Drug Discovery (one of the top Cannabinoid and Serotonin research centers in the world) for over a decade.
- Co-managed $80M + in federal funding for cannabinoid and serotonin research.
- Recognized leader in Psychedelics (co-founder of Psymposia)
- Co-managed the NIDA-sponsored Chemistry & Pharmacology of Drug Abuse (CPDA) conference for 5 years.
Alex Belser Ph.D.
Chief Clinical Officer
- Licensed psychologist, clinical supervisor, and psychedelic researcher at Yale in psilocybin clinical trials.
- Active in the psychedelic research community for 20 years.
- Conducted clinical research with psilocybin and MDMA for a variety of indications.
- Research featured on front page of the NYT, in the Atlantic, the New Yorker, The Guardian, VICE, and in Michael Pollan’s book, How to Change Your Mind.
- Co-Founder and Managing Director of Trinity Venture Partners Inc, a Canadian boutique merchant bank.
- Co-Founder of multiple start-ups across various sectors.
- 10+ years experience in medical device manufacturing and regulatory frameworks.
- Successfully raised over $100M for various start-ups.
Co-Founder and Chief Growth Officer
- Co-founder of Global Canna Brands which was granted the first ever tier 3 cultivation license in Jamaica.
- Sold first cannabis startup Truverra to Supreme Cannabis Company Inc. (TSX:FIRE).
- Has advised on M&A and other financings in excess of $50M.
- Serial entrepreneur and investor with vast experience in the biotech and cannabis sectors.
Chief Financial Officer
- 15+ years experience creating efficient scalable operations financial reporting, IFRS; regulatory reporting OSFI.
- Former Ontario Securities Commission contracted Director of Finance.
- Former Scotiabank senior manager of enterprise functions.
- Former CFO of Global Maxfin Investments Inc.
- Former CIBC small business lending controller. Authority over assets of $31B for external reporting on a monthly and quarterly basis.
Chief Legal Officer
- Counsel with 20 years of corporate/commercial legal experience.
- Responsible for legal, compliance, corporate governance, security and regulatory affairs.
- Previously served as Legal Counsel for the Government of Canada as well as private companies including GrowPacker Inc.
SVP, Clinical Operations
- Passionate about developing novel treatment protocols in CNS therapeutics to advance unmet medical needs. Translate business strategy into optimal solutions by building and partnering with premier providers
- Well networked in developing and nurturing strong Key Opinion Leader (KOL)relationships in Phase I – IV Trials.
- Extensive background in various therapeutic areas (TAs) with a special emphasis on CNS indications. Experience includes, Alzheimer’s, mild cognitive impairment, schizophrenia (CIAS, negative, and positive symptoms), bipolar disorder (mania and depressive state) and MDD.
- Significant experience with the unique challenges in phase I (first in human, SAD, MAD, complex cohort management) and orphan indications (Friederichs’s ataxia, behavioral variant FTD, FTD with Progranulin Mutation).
VP Business Development
- Former Vice President of business development and project management at Purdue Pharma (Canada).
- Former Director of business development at TEVA.
- Former equity research analyst at CIBC World Markets.
Senior Director Clinical Alliances
- Inspirational leader and networker known for building long-term relationships based on trust and being present in the moment.
- Former Senior Director of Business Development at Apex Innovation (HRI) – Apex Innovative Sciences.
- Former Senior Director Business Development at Clinilabs
Joan M. Krakowsky Ph.D
Sr. Director Research & Preclinical Program Coordination
- A unique combination of 25+ years of scientific experience with over a decade of business development and project management experience in the pharmaceutical industry, including Sanofi-Aventis and Sancilio & Company, Inc.
- Research scientist with extensive expertise in GEM (Genetically Engineered Model) development and gene expression profiling studies, leading teams to support research in CNS, Metabolism, Immunology and Oncology.
- Extensive experience as a program manager in the pharmaceutical industry with responsibilities for large-scale global projects.
- Project manager overseeing discovery, preclinical, clinical research and chemical manufacturing programs.
- Bachelor of Science in Biology and Psychology from Boston College.
- Doctor of Philosophy in Biomedical Sciences from Wright State University.
Head of R&D
- Neuroscientist and drug discoverer with a proven record of progressing novel molecular entities into clinical trials.
- Over 20 years of experience in the pharmaceutical industry with scientific leadership and managerial roles in Research & Development at Schering Plough, Sanofi, and Merck.
- Contributed to the clinical testing of several compounds with one of the compounds (rolapitant) approved and marketed as VARUBI for the treatment of chemotherapy-induced nausea and vomiting.
- Managed the out-sourcing of in-vivo studies to Contract Research Organizations (CROs) for Merck’s major therapy areas.
- Published research in over 130 journal articles and abstracts.
VP, IR & Strategic Communications
- A life sciences investor relations leader with nearly two decades of experience in corporate and shareholder communications, and business strategy development.
- Expertise in developing and successfully executing strategic investor relations programs that have cultivated significant shareholder ownership
- Vast experience working with small-, mid- and large-cap publicly traded biotechnology companies in North America, including a $60B large-cap U.S. biotech focused on creating transformative medicines for serious genetic diseases.
- Received the 2019 Institutional Investor award for best investor relations program, ranking #1 by the buy-side
General Counsel & IP Counsel
- Responsible for a wide range of legal matters including contracts, intellectual property, US employment agreements, and contracts for R&D, Pre-clinical, Clinical, Regulatory, and Business Development teams.
- Over 20 years of diverse experience including general counsel, IP attorney, commercial roles, and laboratory researcher
- Registered Patent Attorney, USPTO, Licensed to Practice Law in FL, DC, and MA
- Regulatory Affairs Certificate for Pharmaceutical and Medical Devices, RAPS; Copyright Law Certificate, Harvard University
- JD, MBA, MS (Molecular Genetics, Pharmacology), University of Florida; BS (Genetics, Chemistry), University of Georgia
SVP Chemistry & Manufacturing
- Ph.D. in Organic Chemistry with detailed knowledge of pharmaceutical development.
- Direct detailed experience in synthetic organic, analytical and formulation development chemistry with excellent trouble shooting ability.
- Experience in outsourcing / technology transfer management to domestic and international CROs to support clinical and preclinical projects for drug substance and drug product.
- Former Ontario health minister responsible for one of the largest healthcare systems in North America (2014 – 2018).
- Former elected Member of Ontario Provincial Parliament with Cabinet positions in Health, Economic Development and Trade, Children and Youth Services, and Immigration.
- Government of Canada Chair, Advisory Council on the Implementation of National Pharmacare.
- Physician and public health specialist with more than thirty years’ experience in public policy, complex diplomacy, international affairs, health care, media and economic development at the intersection of business, politics and complex social and political circumstances.
- Proven negotiator and navigator at the highest levels of government and bureaucracy.
Dr. Anthony Back
- Anthony Back is a recognized leader in the fields of palliative care and oncology.
- Board-certified physician at Colorectal Services at University of Washington Medical Center, co-director of the University of Washington Center for Excellence in Palliative Care, and a University of Washington professor of Oncology and Medicine and an adjunct professor of Bioethics and Humanities.
- He is triple board certified in Hospice and Palliative Medicine, Medical Oncology and General Internal Medicine. He was the principal investigator for the Oncotalk interventions, co-wrote Mastering Communication with Seriously Ill Patients, released the first iPhone app for clinician communication skills, and is a Contemplative Studies Fellow of the Mind and Life Institute.
- His clinical and research interests include patient-physician communication and quality of life palliative care.
- Dr. Back earned his medical degree at Harvard Medical School.
- Former Senior Vice President with Shoppers Drug Mart responsible for developing new growth strategies and the connected health network
- 15 years in senior roles with Pfizer Inc in Canada, Europe and Asia, including Regional President, Emerging Markets Asia (China).
- 35 years experience in health care including senior leadership
Dr. Maurizio Fava
- International leader in the field of depression. He serves as Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital and Associate Dean for Clinical & Translational Research, and Slater Family Professor of Psychiatry at Harvard Medical School.
- In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (“CTNI”), the first academic contract research organization (“CRO”) specialized in planning and coordination of multi-center clinical trials in psychiatry.
- He has authored or co-authored more than 800 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 600 abstracts. Dr. Fava earned his medical degree from the University of Padua.
Sherri M. Altshuler
- Partner and Co-Chair of Capital Markets Group at Aird & Berlis LLP.
- co-Practice Group Leader of the firm’s Capital Markets Group.
- Recognized in 2017 as one of Lexpert magazine’s Rising Stars: Canada’s Leading Lawyers Under 40 and, in 2018, as a leading lawyer to watch in the area of Corporate Finance & Securities.
- Sherri is a member of the TSX Venture Exchange Ontario Advisory Committee and a former member of the Ontario Securities Commission Small and Medium Enterprises Committee.
Dr. Thomas Laughren
- Former FDA Director for the Division of Psychiatry products, where he served for 29 years.
- Dr. Laughren was responsible for overseeing the review of all psychiatric drug development activities conducted under INDs and the review of all NDA’s and supplements for new psychiatric claims.
- Prior to joining the FDA in September 1983, Dr. Laughren was affiliated with the VA Medical Center in Providence, RI, and was on the faculty of the Brown University Program in Medicine.
- He has authored and co-authored many papers and book chapters on regulatory and methodological issues pertaining to the development of psychiatric drugs, and is a frequent speaker at professional meetings on these same topics. Dr. Laughren has received numerous awards for his regulatory accomplishments.
Dr. Lynn Marie Morski
- President of the Psychedelic Medicine Association (“PMA”), a society of physicians, therapists and health care professionals looking to advance their education on the therapeutic uses of psychedelic medicines.
- The PMA is a public benefit corporation of health care providers working to bridge the gap between the advances taking place in the psychedelic research world and medical practitioners.
- Morski is also host of the Plant Medicine Podcast, the founder of PlantMedicine.org, and the medical director for WayofLeaf.com.
- She is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor. Dr Morski earned her medical degree at Saint Louis University School of Medicine and her law degree at Thomas Jefferson School of Law.
- Mark Lawson is private equity & investment banking executive with over 20 years of experience in the North American capital markets and is the Managing Partner at Clermont Capital Partners.
- He was previously an investment banker with Morgan Stanley in New York where he was involved in the execution of over $6 billion worth of mergers and acquisitions, $8 billion worth of debt offerings and $500 million of equity financings in the healthcare, technology, and media & telecom sectors.
- He received his Bachelor of Arts in Statistical Sciences from The University of Western Ontario, Canada and his MBA from The Richard Ivey School of Business, University of Western Ontario, Canada.
- Former Chief Operating Officer at Loblaws, Canada’s largest food and drug retailer.
- 38 years experience within the retail industry. Extensive background in merchandising, supply chain management, digital, marketing and innovative strategies.
- Served on various private and public boards.
SVP, Product Development
- Over 25 years in pharmaceutical product development and commercialization with diverse experience in analytical development and pharmaceutical science, portfolio management, regulatory affair, cGMP compliance, business development and M&A.
- Former co-founder and CEO of Sungen Pharma LLC, a privately held specialty pharma company.
- Former VP of generic development at Endo International plc, a global specialty pharma company.
- Former VP of RD and Managing Director, Actavis Florida.
- Other scientific and managerial roles in Elan, Bausch & Lomb, and Abbott Labs.
VP, Corporate Controller
- Former Controller at Knight Therapeutics Inc.
- Former auditor at Ernst & Young
- Holds a Bachelor of Commerce degree and a Graduate Diploma in Public Accountancy from McGill University and is a Chartered Professional Accountant
Sr. Director, Quality Assurance
- 26 years of experience in quality and compliance roles in the pharmaceutical and medical device industries
- BSc. with a major in biology from the University of Western Ontario
- MBA from the Schulich School of Business at York University
Director, Legal & Corporate Services
- 25 years of experience working with leading corporations in administrative support roles to senior leadership.
- 10+ years of law firm and in-house corporate law clerk experience working in rapidly evolving tech-based industries.
- Oversight of national and international legal and corporate matters with specialty in corporate restructuring, tax reorganizations, acquisitions, and public company listings and filings.
- Responsible for maintaining corporate records and database.
- 20+ years of experience in the creation and documentation of business manuals and process to establish appropriate knowledge transfer and enable effective contingency planning.
- Implementation of employee education programs and resource libraries.
- Extensive experience in engaging and supporting senior leadership teams in cross-functional collaboration activities aligned to corporate objectives and strategic goals.
Director, Process Chemistry
- Highly skilled executive with 20+ years of management experience in pharmaceutical development operations, early stage, and late-stage development.
- Strategic professional with proven expertise in CMC ensures that pharmaceutical and biopharmaceutical drug products are consistently effective, safe and high quality.
- Experienced in laboratory research, scale up, and technology transfer to ensure optimal product quality of drugs from R&D to late-stage approval.
- Strong knowledge of establishing strategies for Process Control, Process Qualification and Process Performance Qualification in order to produce coast saving processes and manufacturing of complex molecules from lab to commercial scale.
- Post-doctoral research with Nobel Laureate Prof H.C.Brown, Purdue University.
Director of Information Technology
- IT professional with 20 years experience
- A passion for technology & data insights
- Driving innovative, cost effective, secure IT solutions
Alex Kelman, Ph.D.
Senior Director Training, EMBARK
Dr. Alex Kelman is the Senior Director, Training EMBARK at Cybin and an Attending Psychologist and Assistant Clinical Professor at the University of California, Los Angeles (UCLA). Prior to his current role at Cybin, Dr. Kelman was the Director of Training of the UCLA Prevention Center of Excellence in the Semel Institute for Neuroscience and Human Behavior. Dr. Kelman has published manuscripts on behavioral health equity, mindfulness, compassion, trauma-informed systems of care, and novel methods of service delivery and has done extensive community-based and academic teaching in these areas.
Amy Reichelt, Ph.D.
- Neuroscientist with over 10 years of international experience leading cutting-edge research programs in the neurobiology of obesity, cognition, and neurodegeneration
- Extensive experience in behavioral neuropharmacology, translational medicine, and neurophysiology
- Published over 50 peer-reviewed scientific articles in high-profile neuroscience and medical journals
- Excels in science communication including an invited TEDxSydney talk, and has featured as a neuroscience expert in numerous media outle